The lawsuit centers on allegations that Capricor Therapeutics misled shareholders regarding its clinical data analysis for Deramiocel. According to the complaint, the company modified its pre-specified statistical analysis plan without securing prior FDA agreement before resubmitting its Biologics License Application. These omissions reportedly created a significant risk that the regulatory body would find the clinical results insufficient to prove the drug's effectiveness for treating Duchenne muscular dystrophy.
Capricor Therapeutics Investors Face Class Action Deadline
Investors who incurred significant financial losses linked to Capricor Therapeutics, Inc. have until September 28, 2026, to file as lead plaintiffs in a pending securities fraud class action. The Law Offices of Howard G. Smith is currently organizing the litigation regarding alleged misrepresentations made by the company.
The litigation claims that because these operational shifts were withheld, the company’s public statements concerning its business prospects lacked a reasonable basis. Shareholders who purchased stock during the relevant class period may contact Howard G. Smith at 215-638-4847 or via the firm's website to review their legal rights. Participation as a lead plaintiff is optional, as investors may also choose to remain absent members of the class action or retain independent counsel.
Comments (0)
No comments yet. Be the first!